BIH Center for Regenerative Therapies (BCRT), Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Fraunhofer-Institute for Biomedical Engineering (IBMT), Fraunhofer Project Center for Stem Cell Process Engineering, Würzburg, Germany.
Cell Mol Life Sci. 2023 Aug 24;80(9):265. doi: 10.1007/s00018-023-04901-w.
Transient receptor potential cation channel-6 (TRPC6) gene mutations cause familial focal segmental glomerulosclerosis (FSGS), which is inherited as an autosomal dominant disease. In patients with TRPC6-related FSGS, all mutations map to the N- or C-terminal TRPC6 protein domains. Thus far, the majority of TRPC6 mutations are missense resulting in increased or decreased calcium influx; however, the fundamental molecular mechanisms causing cell injury and kidney pathology are unclear. We report a novel heterozygous TRPC6 mutation (V691Kfs*) in a large kindred with no signs of FSGS despite a largely truncated TRPC6 protein. We studied the molecular effects of V691Kfs* TRPC6 mutant using the tridimensional cryo-EM structure of the tetrameric TRPC6 protein. The results indicated that V691 is localized at the pore-forming transmembrane region affecting the ion conduction pathway, and predicted that V691Kfs* causes closure of the ion-conducting pathway leading to channel inactivation. We assessed the impact of V691Kfs* and two previously reported TRPC6 disease mutants (P112Q and G757D) on calcium influx in cells. Our data show that the V691Kfs* fully inactivated the TRCP6 channel-specific calcium influx consistent with a complete loss-of-function phenotype. Furthermore, the V691Kfs* truncation exerted a dominant negative effect on the full-length TRPC6 proteins. In conclusion, the V691Kfs* non-functional truncated TRPC6 is not sufficient to cause FSGS. Our data corroborate recently characterized TRPC6 loss-of-function and gain-of-function mutants suggesting that one defective TRPC6 gene copy is not sufficient to cause FSGS. We underscore the importance of increased rather than reduced calcium influx through TRPC6 for podocyte cell death.
瞬时受体电位阳离子通道 6 (TRPC6) 基因突变导致家族性局灶节段性肾小球硬化症 (FSGS),该病呈常染色体显性遗传。在 TRPC6 相关 FSGS 患者中,所有突变均位于 N 端或 C 端 TRPC6 蛋白结构域。迄今为止,大多数 TRPC6 突变是错义突变,导致钙内流增加或减少;然而,导致细胞损伤和肾脏病变的基本分子机制尚不清楚。我们报道了一个大型家族中存在一种新的杂合性 TRPC6 突变 (V691Kfs*),尽管 TRPC6 蛋白大部分缺失,但该家族无 FSGS 迹象。我们使用四聚体 TRPC6 蛋白的三维冷冻电镜结构研究了 V691Kfs* TRPC6 突变体的分子效应。结果表明,V691 位于形成孔的跨膜区域,影响离子传导途径,预测 V691Kfs* 导致离子传导途径关闭,从而导致通道失活。我们评估了 V691Kfs* 和之前报道的两种 TRPC6 疾病突变体 (P112Q 和 G757D) 对细胞内钙内流的影响。我们的数据表明,V691Kfs* 完全失活了 TRCP6 通道特有的钙内流,与完全丧失功能表型一致。此外,V691Kfs* 截短对全长 TRPC6 蛋白表现出显性负效应。总之,无功能的 V691Kfs* 截断 TRPC6 不足以导致 FSGS。我们的数据与最近表征的 TRPC6 功能丧失和获得功能突变体一致,表明一个有缺陷的 TRPC6 基因拷贝不足以导致 FSGS。我们强调了通过 TRPC6 增加钙内流而不是减少钙内流对 podocyte 细胞死亡的重要性。